Mager Named Chair of Pharmaceutical Sciences – UBNow: News and Views for UB Faculty and Staff

Donald E. Mager has been appointed chair of the Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, effective July 11.

Mager, an internationally renowned pharmaceutical scientist with a record of accomplishment in pharmacokinetics and pharmacodynamics, received his BS in Pharmacy from UB in 1991 and his PharmD and PhD from UB in 2000 and 2002. He trained post-graduate as an intramural researcher. at the National Institute on Aging, National Institutes of Health, Laboratory of Clinical Investigation in 2004.

He was first appointed to the faculty in 2004, granted tenure and made associate professor in 2010, and promoted to full professor in 2016 and began his term as vice president in 2017. During his tenure, he served as Acting Director of Undergraduate Studies for the Department of Pharmaceutical Sciences,

Mager is also a graduate faculty member in Experimental Therapeutics at Roswell Park Comprehensive Cancer Center and is currently President and CEO of Enhanced Pharmacodynamics, LLC.

In his past work as Vice President of the Department, Mager was instrumental in developing and maintaining strong relationships across the pharmaceutical industry, as well as understanding and appreciating the unique role which the department has played in the development of contemporary pharmaceutical sciences. As Chair, he will continue to reinforce these important roles and focus on departmental leadership in drug development and other evolving areas of pharmaceutical science.

“Don joins a long line of truly distinguished professorships to emerge from the faculty. I have deep respect for the history of this department and its unique role in the development of pharmaceutical sciences, and boundless optimism for its continued success under Don’s leadership,” said Gary Pollack, Dean of the School. of pharmacy and pharmaceutical sciences.

“I would also like to recognize and thank Dr. Marilyn Morris, who has shown exceptional leadership as President over the past six years. She leaves an extremely solid foundation on which Don can build.

Morris led many key initiatives during her six years as President, including the creation of a systems pharmacology, protein engineering and biobased drug delivery program supported by an investment of $1 million dollars from the Empire Innovation Program at the State University of New York, as well as the launch of a new Master of Science program in pharmacometrics and personalized medicine.

Mager has a long tradition of leadership, collaboration and service. He was Associate Editor/Consultant of Pharmacometrics and Systems Pharmacology, Journal of Pharmacology and Experimental Therapeutics and Pharmacology, Research and Perspectives.

He has served on the boards of the International Society of Pharmacometrics and the American College of Clinical Pharmacology and has held senior leadership positions at the American Association of Pharmaceutical Scientists, the American Society for Clinical Pharmacology and Therapeutics, and is a Fellow and Past President of the International Society for Pharmacometrics.

He is currently a Fellow and President of the American College of Clinical Pharmacology, and an appointed member of several scientific organizations, including the American Academy for the Advancement of Science, the American Association of Pharmaceutical Scientists, and the International Pharmaceutical Federation.

“I am deeply touched and honored to be named the next Chair of the Department of Pharmaceutical Sciences. I would like to add my appreciation to Dr. Marilyn Morris and past presidents, Drs. William Jusko and Ho-Leung Fung for outstanding management,” says Mager.

“Our department has a rich tradition of excellence, and I am delighted to work with all members of our department and our school to maintain this tradition while advancing the discovery and dissemination of new knowledge in the search for innovative therapies. and improved.”

Mager is a research leader in systems pharmacology and pharmacodynamics. His important contributions include the creation of new theoretical concepts and new applications related to the elimination of targeted drugs, the evaluation of the properties of monoclonal antibodies and the development of cancer chemotherapy models.

He has received consistent federal and industry funding over the course of his career, has published over 155 articles in peer-reviewed journals, and has been a guest speaker at over two hundred national and international meetings and symposia.